Johnson & Johnson on Tuesday narrowed its guidance ranges for its full-year profit and revenue results, leaving the midpoints of the guidance nearly unchanged.
The New Brunswick, N.J.-based pharmaceutical and healthcare company said it now estimates its full-year sales will be $90.6 billion to $91.6 billion, compared with a previous estimate of $90.5 billion to $91.7 billion. Analysts had been forecasting full-year revenue of $92.18 billion, according to FactSet.
Johnson & Johnson expects adjusted earnings per share for the full year of $9.42 a share to $9.57 a share. In January, it had forecast $9.40 a share to $9.60 a share. Analysts had been anticipating full-year adjusted earnings of $9.50 a share.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.